Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R.J. Chan
Idelalisib Plus Anti-Cd20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Treatment Emergent Adverse Events Vary With Different Pi3k Inhibitors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer
Journal of Cancer
Oncology
Early Second‐line Therapy Is Associated With Improved Episodic Memory in Anti‐NMDA Receptor Encephalitis
Annals of Clinical and Translational Neurology
Neuroscience
Neurology
Idelalisib Bolsters CLL Regimen
Cancer Discovery
Oncology
Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
First-Line Ibrutinib Confirmed for CLL
Cancer Discovery
Oncology
Pediatric Response to Second-Line Antiretroviral Therapy in South Africa
PLoS ONE
Multidisciplinary
First-Line Therapy of CD20+ Diffuse Large B-Cell Lymphoma: Facts and Open Questions
Haematologica
Hematology
Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-Line Therapy for Patients With Autoimmune Hepatitis
Clinical Gastroenterology and Hepatology
Hepatology
Gastroenterology
Switching Multiple Sclerosis Patients With Breakthrough Disease to Second-Line Therapy
PLoS ONE
Multidisciplinary
